Tokyo–REGiMMUNE Corporation (“REGiMMUNE” or “the Company”), a biopharmaceutical Company developing innovative therapeutics for the treatment of immune disorders, is presenting tomorrow at 4:00 pm Eastern. Mr. Haru Morita, President and CEO, will present a corporate update at The 21st Annual the Future Leaders in the Biotech Industry 2014.
Presentation Information:
Date:
Friday, March 28th, 2014
Time:
4:00 – 4:30 pm Eastern
Location:
Millennium Broadway Hotel & Conference Center New York City
145 West 44th Street, New York, NY
https://www.biocentury.com/conferences/futureleaders/dates
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan. REGiMMUNE is headquartered in Tokyo, Japan and has a US operation in San Francisco, California. For more information, visit www.regimmune.com.